Jochen Hampe
Scientific Speaker
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (27)
Year:
2026
Year:
2026
Purpose: Handheld ultrasound (HHUS) devices are increasingly used in clinical practice due to their portability and cost-effectiveness. However, HHUS image quality remains variable, and a standardized expert-based evaluation protocol is lacking. This study compares the image quality of B-mode recordings of five HHUS models with a high-end reference system (HEUS) using a blinded assessment to identify differences, covariates, offering a standardized evaluation framework. Materials and Methods: In this blinded, multi-center study, video sequences of the liver, pancreas, and sigmoid colon were recorded in ten volunteers using five HHUS devices - Vscan Air, Butterfly iQ+, Philips Lumify, Clarius C3, and Clarius C3 HD3 - and one HEUS (GE Logiq E10). 22 physicians with many years of abdominal ultrasound experience rated blinded clips for five image quality parameters. Results: The HEUS consistently received the highest ratings. Image quality differed significantly between HHUS devices. Clarius systems showed the smallest deviation from the reference, followed by Vscan Air and Philips Lumify. All image parameters significantly correlated with the overall impression, without a single dominant factor. The patients´ BMI had no relevant influence. Examiner experience was less impactful than device familiarity and personal preference. Conclusion: The image quality of HEUS remained superior to all tested HHUS devices. Further subdivision of image quality aspects did not provide additional information. Furthermore, we could not identify significant covariates in our setup. These findings could justify simplified setups with reduced questionnaires and requirements for examiners. Zielsetzung: Portable Ultraschallsysteme (HHUS) finden aufgrund ihrer Mobilität und Kosteneffizienz zunehmend Anwendung in der Praxis. Ihre Bildqualität ist jedoch variabel und ein standardisiertes, expertenbasiertes Bewertungsprotokoll fehlt bislang. Ziel dieser Studie ist der Vergleich von fünf HHUS-Modellen gegenüber einem High-End-Referenzsystem (HEUS) in einem verblindeten Design sowie die Analyse relevanter Kovariablen, die zur Entwicklung eines standardisierten Bewertungsverfahrens beitragen können. Material und Methoden: In dieser multizentrischen, verblindeten Studie wurden Videos von Leber, Pankreas und Sigma bei 10 Probanden mit fünf HHUS-Geräten (Vscan Air, Butterfly iQ+, Philips Lumify, Clarius C3 und C3 HD3) sowie einem HEUS (Ge Logiq E10) aufgezeichnet. 22 Experten mit langjähriger Ultraschallerfahrung bewerteten die verblindeten Videos nach verschiedenen Kriterien zur Bildqualität. Ergebnisse: Das HEUS erzielte die besten Bewertungen, die HHUS unterschieden sich signifikant. Clarius-Systeme wichen am wenigsten vom HEUS ab, gefolgt von Vscan Air und Philips Lumify. Alle Bildparameter korrelierten signifikant mit dem Gesamteindruck, ohne dass ein dominanter Parameter identifizierbar war. Der BMI hatte keinen relevanten Einfluss. Die Erfahrung der Gutachter war weniger entscheidend als Gerätevertrautheit und persönliche Präferenz. Schlussfolgerung: Die Bildqualität des HEUS war allen getesteten HHUS überlegen. Eine weitere Unterteilung in einzelne Aspekte der Bildqualität lieferte keine zusätzlichen Informationen. Es wurden keine relevanten Kovariablen identifiziert, was für die Etablierung vereinfachter Bewertungsprotokolle mit reduzierten Fragebögen spricht.
Year:
2026
Year:
2026
Anastomotic failure remains one of the most severe complications in gastrointestinal surgery. Despite continuous advancements in stapler technologies and surgical techniques, it continues to be a leading cause of postoperative morbidity and mortality. It contributes substantially to prolonged hospitalization and increased healthcare expenditures. Currently, diagnosis is based on secondary systemic signs, such as inflammatory response or changes in drain fluid, followed by a multimodal diagnostic approach. However, reliable early detection of local alterations is still lacking. Here, the implantation of a bioresorbable is investigated, intra‐anastomotically placed sensor device. By performing real‐time intra‐anastomotic bioimpedance measurements, ischemia‐related changes are identified at an early, potentially reversible stage, prior to the onset of clinical or systemic manifestations. Furthermore, the sensor device offers the potential for future integration of pattern‐recognition algorithms and the possibility of direct measurement of different markers in the anastomotic microenvironment.
Year:
2026
Background Anastomotic leakage (AL) represents one of the most serious complications in gastrointestinal surgery, with reported incidence rates of up to 26%. Despite advancements in surgical techniques, early detection of AL remains challenging, and no reliable real-time monitoring system is currently available. In this study, we investigated a resorbable polydioxanone (PDO) membrane as a potential substrate for future sensor integration, aiming to facilitate real-time monitoring of anastomotic healing. Methods In eight German Landrace pigs, 34 ileal side-to-end stapler anastomoses were examined: GM1 ( n = 7), GM2 ( n = 10), and controls ( n = 17). Membrane stability was monitored after implantation, while adhesion formation, burst pressure, and histology were assessed on postoperative day 7. Results Both membrane geometries showed robust stability, with good anchorage of the large spokes within the anastomosis. Geometry 1 (GM1) exhibited higher burst pressure than Geometry 2 (GM2) (193 ± 43.6 vs. 155 ± 65.5 mmHg, p = 0.02). Compared with controls (167 ± 42.3 mmHg), neither GM1 ( p = 0.053) nor GM2 ( p = 0.379) differed significantly. Adhesions occurred in all groups, without significant differences. Histological evaluations showed typical granulation tissue and fibrosis, with granulocytic inflammation more common in GM1 without affecting anastomotic stability. Conclusion This proof-of-concept study demonstrates that the PDO membrane can be safely incorporated into stapled anastomoses without compromising anastomotic healing. The membrane provides a stable, biocompatible platform suitable for future sensor integration, supporting the development of a diagnostic intraanastomotic device.
Year:
2026
Year:
2026
Background The role of lipid-perturbing medications in cancer risk is unclear. Methods We employed cis-Mendelian randomization and colocalization to evaluate the role of 5 lipid-perturbing drug targets (ANGPTL3, ANGPTL4, APOC3, CETP, and PCSK9) in risk of 5 cancers (breast, colorectal, head and neck, ovarian, and prostate). We triangulated findings using pre-diagnostic protein measures in prospective analyses in EPIC (977 colorectal cancer cases, 4080 sub-cohort members) and the UK Biobank (860 colorectal cancer cases, 50 177 controls). To gain mechanistic insight into the role of ANGPTL4 in carcinogenesis, we examined the impact of the ANGPTL4 p. E40K loss-of-function variant on differential gene expression in normal colon tissue in BarcUVa-Seq. Finally, we evaluated the association of colon tumor ANGPTL4 expression with cancer-specific mortality in TCGA. Results In analysis of 78 473 cases and 107 143 controls, genetically proxied circulating ANGPTL4 inhibition was associated with reduced colorectal cancer risk (ORSD decrease = 0.76, 95% confidence interval [CI] = 0.66 to 0.89, P = 5.52 × 10−4, PPcolocalization = 0.83). This association was replicated using pre-diagnostic circulating ANGPTL4 concentrations in EPIC (hazard ratio [HR]log10 decrease = 0.91, 95% CI = 0.84 to 0.98, P = .01) and the UK Biobank (HRSD decrease = 0.93, 95% CI = 0.86 to 0.99, P = .03). In gene-set enrichment analysis of differential gene expression in 445 colon tissue samples, ANGPTL4 loss-of-function down-regulated several cancer-related biological pathways (PFDR < .05), including those involved in cellular proliferation, epithelial-to-mesenchymal transition, and bile acid metabolism. In analysis of 465 colon cancer patients, lower ANGPTL4 tumor expression was associated with reduced colorectal cancer-specific mortality risk (HRlog2 decrease = 0.66, 95% CI = 0.50 to 0.87, P = 2.92 × 10−3). Conclusions Our integrative proteogenomic and observational analyses suggest a potential protective role of lower circulating ANGPTL4 concentrations in colorectal cancer risk. These findings support further evaluation of ANGPTL4 as a therapeutic target for colorectal cancer prevention.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Collaborators (48)
Li Hsu
Fred Hutchinson Cancer Research Center
Polly Newcomb
University of Washington
Marc Gunter
International Agency for Research on Cancer
Tabitha Harrison
Fred Hutchinson Cancer Research Center
Konstantinos K. Tsilidis
-
Victor Moreno
Professor
University of Barcelona
Emma Vincent
Academic , Professor of Molecular Metabolism
University of Bristol
Fränzel J.B. van Duijnhoven
Wageningen University & Research
John Baron
Professor
University of North Carolina
Alexander Hann
Professorship for Digital Transformation in Gastroenterology
University Hospital Würzburg
Ulrike Peters
Fred Hutchinson Cancer Research Center
Jihyoun Jeon
University of Michigan
Ruifang Li-Gao
Researcher
Leiden University Medical Center
James Yarmolinsky
Imperial College London
Hans Kleemann
Academic Staff
Technische Universität Dresden
Elizabeth Platz
Professor
Johns Hopkins University
Ko Willems van Dijk
Professor
Leiden University Medical Center
Yingye Zheng
Fred Hutchinson Cancer Research Center
Tim Bishop
University of Leeds
Elizabeth Hauser
Duke University
Karl Leo
Technische Universität Dresden
Richard Hayes
Professor of Population Health and Environmental Medicine
NYU School of Medicine
Mingyang Song
Associate Professor
Harvard University
Alicja Wolk
Professor of Nutritional Epidemiology
Karolinska Institutet
Anna H. Wu
Professor
University of Southern California
John Potter
Professor
University of Washington
Bethany Van Guelpen
Umea University
Li Li
University of Virginia
Iris Lansdorp-Vogelaar
Associate Professor
Erasmus University Medical Center
Verena Plodeck
-
Kai Uhlig
Group leader
Leibniz-Institut für Polymerforschung Dresden e.V.
Andrea Burnett-Hartman
Epidemiologist Program Director
Fred Hutchinson Cancer Research Center
Andrea Gsur
Medical University of Vienna
Loic Le Marchand
Professor
University of Hawaii
Karlheinz Bock
Technische Universität Dresden
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Graham Casey
University of Virginia
Daniel D. Buchanan
Senior Research Fellow
University of Melbourne
Tom Dudding
Consultant Senior Lecturer Restorative Dentistry
University of Bristol
Annika Lindblom
Karolinska Institutet
Stephen Gruber
Professor
City Of Hope National Medical Center
Mark Jenkins
University of Melbourne
Peter T. Campbell
Professor
Albert Einstein College of Medicine
Graham Giles
Head of Research
-
Michael Hoffmeister
Professor of Epidemiology, Group leader, Deputy divison head
German Cancer Research Center (DKFZ)
Elizabeth Barry
Associate Professor
Dartmouth College Geisel School of Medicine
Pavel Vodička
senior researcher
Charles University
Andreas Richter
Dean
Technische Universität Dresden
Make your next move.
Prepare your application
Review drafts before you send them.